CION Ameerpet
“You are in remission” is good news, and it is also a precise clinical statement that is easy to mishear. Complete remission means nothing can be found — not on examination, not on the scan, not in your blood. It is not the same word as cured, and knowing the difference makes the months ahead easier rather than harder.
Remission means the cancer has responded to treatment — the signs of it have shrunk or disappeared. In ovarian cancer that judgement is made from three things read together: a clinical examination, a CT scan of the chest, abdomen and pelvis, and the CA-125 trend. When all three are clear, your team will say complete remission, or complete response, or no evidence of disease. Those three phrases mean the same thing.
Most people who search ovarian cancer remission want an answer to one question: is it gone? The honest answer is that remission describes what can be found, not what exists. A CT scan resolves deposits down to a few millimetres at best, and ovarian cancer characteristically spreads as a thin scatter of tiny deposits across the peritoneal surfaces. Complete remission means nothing is visible at that resolution. It does not prove that nothing is there.
That is not a reason to discount the news. A complete remission is exactly what first-line surgery and chemotherapy set out to achieve, and it is what makes a long disease-free interval — and, for some women, cure — possible at all. It is a reason to keep the follow-up appointments rather than assume the chapter has closed, and, where the tumour biology allows it, to consider maintenance treatment intended to hold the remission for longer.
Nothing detectable on examination, on imaging or in the CA-125. Written on reports as complete response, or as NED — no evidence of disease.
Disease that is measurably smaller but still visible. Under RECIST criteria that means at least a 30% fall in the summed diameters of the measured lesions.
Remission is judged now, from the tests in front of your team. Cure is only ever recognised backwards, from years that pass without the disease returning.
“Complete remission” is a measurement statement, not a biological one. Under RECIST 1.1 — the response criteria used in ovarian cancer trials worldwide — a complete response means every target lesion has disappeared on imaging and any lymph node has fallen below 10 mm in short axis. Under the Gynecologic Cancer InterGroup’s CA-125 criteria, a marker response means a fall of at least 50% from the pre-treatment value, maintained for at least 28 days. Both definitions describe what can no longer be seen or measured. Neither claims that no cancer cell remains — a CT scan cannot resolve peritoneal deposits only a few millimetres across, which is precisely how ovarian cancer tends to spread. Source: Eisenhauer EA et al., RECIST 1.1, European Journal of Cancer (2009); Rustin GJS et al., GCIG CA-125 response criteria, International Journal of Gynecological Cancer (2011).
End-of-treatment letters use a vocabulary borrowed from clinical trials. The words are precise, and they are not interchangeable. Here is what each one is actually claiming.
| Term you may see | What it means | What it does not mean |
|---|---|---|
| Complete remission / complete response | No cancer visible on examination or imaging, and a CA-125 that has returned to normal. Also reported as NED, no evidence of disease. | That every cancer cell has gone. Imaging cannot see deposits of a few millimetres, and a normal CA-125 does not exclude them. |
| Partial remission / partial response | Measurably smaller disease that is still visible — under RECIST, a fall of at least 30% in the summed diameters of the measured lesions. | A failure. A partial response can still be worth consolidating, and in some women it deepens after treatment ends. |
| Stable disease | Neither shrinking enough to count as a response nor growing enough to count as progression. | That nothing is happening. In a slow-growing low-grade tumour, stability held over months is a genuine result. |
| Progressive disease | Growth of at least 20% in the summed diameters, or a new lesion, or a CA-125 rise meeting the GCIG definition. | That treatment has failed permanently. It means this line of treatment has stopped working and the plan changes. |
| No evidence of disease (NED) | Everyday shorthand for a complete remission — nothing can be found by the tests being used. | A different or better result than complete remission. It is the same finding in plainer words. |
| Cured | A word reserved for a remission that has lasted long enough, with no relapse, that the risk of return has become very small. | Anything a scan or a blood test can confirm today. Cure is a conclusion drawn from time, not from a result. |
*Response criteria describe measurable disease. Where ovarian cancer is present only as tiny peritoneal deposits, there may be nothing measurable to report against, and the CA-125 trend and the clinical examination carry more of the weight.
Cure means the disease will never return. Nothing measurable can demonstrate that on the day treatment finishes, which is why a careful oncologist will not say it then. Remission is a statement about the present, made from the tests in front of them. Cure is a conclusion drawn later, from years that pass without a relapse. Both words can be true of the same woman — just not at the same moment.
The distinction matters most in high-grade serous ovarian cancer, the commonest type, which is usually diagnosed only after it has spread across the peritoneum. It typically responds well to platinum-based chemotherapy, so complete remissions are common; it also relapses more often than early-stage disease. Completely removed, completely treated early-stage disease is a different situation, and there cure is a realistic word to use carefully, with time behind it.
Sitting between the two is a fact worth holding on to: a relapse is not a return to the beginning. Ovarian cancer that comes back is often treatable again, sometimes for years, and the interval since the last platinum dose largely decides what is offered next — the subject of our guide to ovarian cancer recurrence and the platinum-free interval. Many women live through long remissions punctuated by treatment, which is a very different prospect from the one the word incurable tends to conjure.
Not to manage your hopes downwards. There is no test that can confirm cure, and your team will not claim something it cannot show you.
The longer a complete remission holds, the less likely a relapse becomes. In advanced disease, most relapses happen in the first few years after treatment.
Cure is realistic in completely resected early-stage disease. In advanced disease the aim is often a long, well-controlled remission — which can still mean years of ordinary life.
Most new aches during remission turn out to be the after-effects of treatment, or something entirely unrelated. Reporting them early is not overreacting, and it does not commit you to starting treatment again — it only means someone competent looks.
A waistband tightening again, or abdominal fullness present on most days for two weeks or more, is worth a call rather than a wait.
Pelvic, abdominal or back pain that is new, or that needs steadily stronger painkillers, should be assessed rather than absorbed into daily life.
Colicky pain, vomiting or a clear change in bowel habit can signal obstruction. This one warrants same-day contact, not a routine appointment.
New breathlessness, or an abdomen enlarging over days rather than months, suggests fluid collecting and needs prompt review.
Ring the clinic rather than searching for the number. A rise is a trigger for a conversation and often a scan — not automatically for treatment.
Unintended weight loss, or fatigue deepening months after chemotherapy rather than easing, deserves an explanation.
Between planned visits, ring your treating team rather than waiting for the next slot. If you are unsure whether a symptom counts, that uncertainty is itself the reason to ask — and see what a structured follow-up and surveillance plan should contain.
Bring your end-of-treatment scan, your CA-125 results and your chemotherapy dates. In 45 minutes a specialist can tell you which response you have actually been given, whether maintenance therapy is open to you, and what your follow-up should look like.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
The first consultation is free and no referral is needed. If the follow-up plan you already have is the right one, we will say so plainly.
Remission is not an empty waiting period, and it should not feel like being discharged into silence. It has a defined shape, and knowing that shape removes a good deal of the anxiety.
An examination, a CT scan of the chest, abdomen and pelvis, and a CA-125, read together. This is the point at which the response is named — complete, partial, stable or progressive — and the word used in that letter shapes everything that follows. If the letter does not say it plainly, ask for it plainly.
For many women with advanced disease in remission after platinum-based chemotherapy, treatment does not simply stop. PARP-inhibitor-class maintenance therapy, guided by BRCA and HRD status, and anti-angiogenic maintenance in selected patients, are intended to lengthen the remission. If BRCA and HRD testing was never done, it belongs in this conversation, because it changes what is available.
Review with examination is typically every two to four months through the first two years, stretching to three to six monthly in years three to five and annually thereafter, in line with published guideline schedules. CA-125 is followed where it was raised at diagnosis. Scans are done for a reason — a symptom, or a marker trend — rather than as routine.
One raised value is not a relapse; the trend across several results is what matters. Even a confirmed rise does not always mean starting treatment that week, because treating a rising marker in a woman with no symptoms has not been shown to help her live longer. It means assessment. Our guide to what happens at relapse covers that decision in full.
Chemotherapy-related neuropathy, fatigue, surgical menopause and its effect on bone health, appetite and weight, and the dread that arrives before every scan are all part of remission, and all treatable in their own right. Nutrition support, survivorship follow-up and psycho-oncology are delivered in-house at CION rather than left to you to arrange.
If the disease returns, the plan is rebuilt around the interval since your last platinum dose, the tumour biology and how you are physically. That may mean chemotherapy again, a change of maintenance, or a trial, and in carefully selected women a further operation coordinated with a specialist partner centre. See ovarian cancer treatment in Hyderabad for how those options fit together.
*Follow-up intervals are typical guideline-based schedules, adjusted to your stage, treatment and symptoms. Your own plan should be written down and handed to you — if it has not been, ask for it.
Remission is the point at which women most often fall through the gaps. Treatment finishes, the intensity of contact drops away, and the questions that matter — which response was I actually given, is maintenance therapy open to me, how often should I be seen, what am I watching for — go unasked, because there is no longer an appointment in which to ask them.
The first consultation at CION is free and runs to about 45 minutes: long enough to read the operation note, the chemotherapy dates, the CA-125 trend and the end-of-treatment scan properly, and to write down a follow-up plan you can keep. Cases are reviewed at a tumour board rather than settled by one clinician, and where the evidence is genuinely uncertain you will be told that instead of being given false precision.
What CION delivers in-house is medical oncology: chemotherapy, maintenance therapy, genetic counselling, BRCA and HRD testing, nutrition support and survivorship follow-up, across 35+ centres in Telangana and Andhra Pradesh. Surgery, HIPEC, intraperitoneal chemotherapy and PET-CT are coordinated with specialist gynaecologic-oncology partner centres and may be billed there. We would rather set that division out now than have you discover it midway through a plan.
Long enough to establish which response you were actually given, and what your follow-up should be, rather than repeating the summary you already have.
BRCA and HRD testing with genetic counselling, in-house. Where it was skipped at diagnosis, it can open maintenance therapy that is otherwise never considered.
Reviews, blood tests and any maintenance treatment across 35+ centres, so years of surveillance do not become years of travelling.
Scans are ordered when a symptom or a marker trend justifies them. Decisions for healing, not billing — and we will say so when nothing needs doing.
Remission means the cancer has responded to treatment. In complete remission, nothing can be found on clinical examination, on a CT scan of the chest, abdomen and pelvis, or in the CA-125 result — the same finding your team may write as complete response or no evidence of disease. In partial remission, the disease is measurably smaller but still visible on imaging. The important limitation is that remission describes what the available tests can detect. A CT scan cannot resolve deposits only a few millimetres across, and ovarian cancer spreads characteristically as tiny peritoneal deposits, so a complete remission is not proof that no cancer cell remains anywhere in the abdomen.
No, and the difference is not a technicality. Remission is a statement about what can be measured today. Cure means the disease will never come back, and no scan or blood test can demonstrate that at the end of treatment — it is only recognised in hindsight, after enough years have passed without a relapse. In completely removed, completely treated early-stage ovarian cancer, cure is a realistic word to use carefully once time has gone by. In advanced high-grade disease, complete remissions are common and relapse is also common, so the aim is often a long, well-controlled remission rather than a promise nobody can keep. An oncologist avoiding the word cure is being honest, not pessimistic.
Complete remission means nothing is detectable: no disease on examination or imaging, and a CA-125 within the normal range. Partial remission means the disease has shrunk substantially but is still visible — under the RECIST criteria used internationally, a fall of at least 30% in the summed diameters of the measured lesions. A partial remission is a real response, not a failure. Depending on the situation it may be consolidated with further treatment, watched to see whether it deepens after chemotherapy ends, or reassessed with a repeat scan. What it does mean is that measurable disease is still present, so the follow-up plan and the discussion about maintenance therapy are usually different from those after a complete remission.
Nobody can answer that with certainty, and any doctor who tells you otherwise is going beyond the evidence. A clear scan and a normal CA-125 together are the best result first-line treatment can produce, and that is genuinely good news. But both tests have limits: CT cannot see deposits of a few millimetres, and CA-125 can sit within the normal range while small volumes of disease persist. That is the whole reason remission is followed with a planned schedule of reviews rather than closed off, and the reason maintenance therapy is offered to some women even when nothing at all can be found. Live in the remission, and keep the appointments.
It varies enormously, and published averages will not tell you about your own situation. What shapes the length of a remission is the stage at diagnosis, the tumour type and grade, whether all visible disease was removed at surgery, how completely the CA-125 normalised during chemotherapy, and whether maintenance therapy suits your tumour biology. Early-stage disease that is completely resected and treated frequently never returns. Advanced high-grade disease relapses more often, usually within the first few years, and the longer a remission holds the less likely a relapse becomes. If it does return, that is not the beginning again — the interval since your last platinum treatment largely decides what is offered next.
That is exactly the conversation to have, because maintenance is given precisely to women in remission — its purpose is to hold the remission for longer, not to treat visible disease. Whether it suits you depends on your stage, how the cancer responded to platinum-based chemotherapy, and your BRCA and HRD status, which is why that testing matters even after treatment has finished. PARP-inhibitor-class maintenance and anti-angiogenic maintenance are the two broad options, each with its own side-effect profile and monitoring requirements, and neither is automatic. If BRCA and HRD testing was never done at diagnosis, ask about it now: it can change what is available to you.
The first consultation is free and runs to about 45 minutes. CION delivers medical oncology for ovarian cancer in-house — chemotherapy, maintenance therapy, genetic counselling with BRCA and HRD testing, nutrition support and survivorship follow-up — across more than 35 centres in Telangana and Andhra Pradesh, so surveillance during remission does not mean repeated long journeys. Surgery, HIPEC, intraperitoneal chemotherapy and PET-CT are coordinated with specialist gynaecologic-oncology partner centres and may be billed there, and we say so at the outset rather than leaving it to be discovered later. Every case that raises a question is reviewed at a tumour board rather than decided by one doctor.